Full text
PDFPage 1277
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
- Dati F. Standardization of commercial assays for serum Apo A-I and Apo B: a consensus procedure for the calibration of reference materials. Scand J Clin Lab Invest Suppl. 1990;198:73–79. [PubMed] [Google Scholar]
- Ford R. P. Essential data derived from biological variation for establishment and use of lipid analyses. Ann Clin Biochem. 1989 May;26(Pt 3):281–285. doi: 10.1177/000456328902600314. [DOI] [PubMed] [Google Scholar]
- Sniderman A. D., Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis. 1990 Sep-Oct;10(5):665–667. doi: 10.1161/01.atv.10.5.665. [DOI] [PubMed] [Google Scholar]
- Vega G. L., Grundy S. M. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 1990 Sep-Oct;10(5):668–671. doi: 10.1161/01.atv.10.5.668. [DOI] [PubMed] [Google Scholar]